Reviewing Ozempic and Zepbound Eye Damage Lawsuit Compensation

Practice Area:Corporate
Jurisdiction:New York

Ozempic and Zepbound eye damage lawsuit compensation requires evidence of liability, causation, and individual losses.

For patients in New York, a claim review compares the medication, treatment dates, and eye diagnosis with the warnings available during treatment. Prescription and eye records help identify gaps. Work records and assistance needs show how vision loss affects daily life.



1. What Supports a Claim for Compensation?


A diagnosis documents an injury. A claim must also connect that injury to the medication and the manufacturer's alleged wrongdoing.


Separate Estimates from Verified Settlements

An online estimate is not an established average payout. Amounts from stomach-injury cases or unrelated lawsuits cannot establish the value of an Ozempic NAION lawsuit.

A claimed “$2 billion settlement” needs a verified agreement identifying the drugs and injuries covered. A firm's results in other cases do not establish a settlement fund for these claims.

Show How Vision Loss Changed Daily Life

Depending on the applicable law and evidence, compensatory damages may address:

  • Medical bills and supported future care costs.
  • Lost earnings and reduced ability to work.
  • Vision aids, transportation, and necessary assistance.
  • Pain, suffering, and reduced enjoyment of life.

Keep bills, wage records, and receipts. Describe specific changes, such as needing help reading medication labels or being unable to complete work tasks.

A doctor's assessment of lasting limitations can support future losses. The diagnosis alone does not establish their value.


2. Match Medication Use to the Eye Diagnosis


Separate prescription dates, actual use, first symptoms, and diagnosis. These dates may differ.


Trace Each Product Separately

Ozempic contains semaglutide and is made by Novo Nordisk. Zepbound contains tirzepatide and is made by Eli Lilly. Keep separate histories if you used both.

RecordWhat to CheckPurpose
Prescription and pharmacy historyBrand, strength, prescriber, refillsIdentifies the product supplied
Injection log or personal notesActual use, missed doses, switchesClarifies exposure dates
Eye examinationsSymptoms, diagnosis, test resultsDocuments the injury
Earlier medical recordsPrevious eye problems and relevant conditionsHelps assess other explanations

Prescription and pharmacy history

  • What to CheckBrand, strength, prescriber, refills
  • PurposeIdentifies the product supplied

Injection log or personal notes

  • What to CheckActual use, missed doses, switches
  • PurposeClarifies exposure dates

Eye examinations

  • What to CheckSymptoms, diagnosis, test results
  • PurposeDocuments the injury

Earlier medical records

  • What to CheckPrevious eye problems and relevant conditions
  • PurposeHelps assess other explanations

A refill proves that medication was supplied, not when it was injected. Mark uncertain dates rather than guessing.

Confirm the Diagnosis and Other Risks

NAION means non-arteritic anterior ischemic optic neuropathy. Reduced blood flow damages part of the optic nerve and can cause lasting vision loss.

Blurred vision alone does not establish NAION. Obtain the diagnosis, visual field tests, optic nerve imaging, and earlier examinations.

Diabetes, high blood pressure, sleep apnea, and smoking may also matter. These risks do not automatically defeat a claim. Their role needs medical assessment.

Sudden vision loss requires prompt medical attention. Discuss medication changes with the treating clinician.


3. Compare Warnings with the Treatment Timeline


Diagram: Four independent review areas show why a regulatory warning alone does not establish an individual drug injury claim.
Diagram: Four independent review areas show why a regulatory warning alone does not establish an individual drug injury claim.

The current label may differ from the information available when treatment began. Preserve dated prescribing information, pharmacy materials, and messages about risks.


Understand What the FDA Required

On November 9, 2026, the FDA required GLP-1 manufacturers to add information about a potential increased risk of NAION to the Warnings and Precautions section.

Ozempic and Zepbound fall within that announcement. The announcement date and each product's actual label revision date remain separate facts.

A Zepbound eye warning review should therefore examine the relevant historical label, rather than relying only on today's webpage.

Establish More Than Timing

A regulatory warning addresses a potential risk. An individual GLP-1 vision loss claim needs evidence connecting the particular drug to that patient's injury.

Claims involving defective drugs may also examine what the manufacturer knew and whether its warnings were adequate.

Under New York's learned intermediary rule, prescription-drug warnings generally run through the prescribing physician. What the physician knew and whether a different warning would have changed treatment can matter.

Medical opinions, research, and prescribing evidence answer different questions. Symptoms appearing after treatment do not establish the entire claim. Federal labeling law may also affect whether a state-law warning claim can proceed.


4. Check the Litigation Process and Filing Deadline


Federal coordination manages related lawsuits. State law may still govern liability, damages, and filing deadlines.


Distinguish the Two GLP-1 Mdls

MDL 3163 concerns alleged NAION injuries. MDL 3094 concerns alleged gastrointestinal injuries. Both proceedings are in the Eastern District of Pennsylvania.

The July 2, 2026 order in MDL 3163 expressly lists Ozempic and Zepbound among the products involved. Inclusion does not establish individual eligibility or liability.

An MDL generally coordinates separate lawsuits for pretrial work. It does not automatically create a certified class action or a shared payout.

This distinction matters in pharmaceutical injury litigation. Submitting an intake form does not establish that someone has filed your lawsuit.

Identify When the Filing Clock Started

Where CPLR §214-c applies to latent effects of substance exposure, the general period is three years from injury discovery. Earlier discovery through reasonable diligence can start the clock sooner.

Learning about the injury differs from learning its possible cause. Section 214-c contains a limited cause-discovery provision with additional requirements.

Do not assume the FDA announcement restarted a deadline. Applicable law, residence, injury location, and claim type need review. Waiting for a settlement in another case does not resolve those questions.


5. Prepare the Records for Review


Bring your medication history, eye records, symptom dates, and documents showing financial or daily limitations. Identify missing records and distinguish recollections from documented facts.

If you switched medications, record the dates, reason for switching, and eye findings around the change. Do not assign the injury to the last drug used based only on timing.

Missing records need not prevent an initial review. Pharmacy histories, insurance claims, and patient portals may help locate them, although they may not replace clinical notes.

For questions about Ozempic and Zepbound eye damage lawsuit compensation, SJKP LLP can assess the available evidence and filing issues. The review should identify supporting facts and questions that remain unresolved.


17 Nov, 2026


The information provided in this article is for general informational purposes only and does not constitute legal advice. Prior results do not guarantee a similar outcome. Reading or relying on the contents of this article does not create an attorney-client relationship with our firm. For advice regarding your specific situation, please consult a qualified attorney licensed in your jurisdiction.
Certain informational content on this website may utilize technology-assisted drafting tools and is subject to attorney review.

Online Consultation
Phone Consultation